Provided by Tiger Trade Technology Pte. Ltd.

OPUS GENETICS INC

5.41
-0.4100-7.04%
Post-market: 5.460.0500+0.92%19:51 EDT
Volume:2.34M
Turnover:12.79M
Market Cap:450.09M
PE:-4.19
High:5.80
Open:5.80
Low:5.35
Close:5.82
52wk High:7.07
52wk Low:1.35
Shares:83.20M
Float Shares:64.45M
Volume Ratio:0.17
T/O Rate:3.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2925
EPS(LYR):-0.8000
ROE:-4796.52%
ROA:-48.06%
PB:-34.66
PE(LYR):-6.76

Loading ...

LifeSci Capital Remains a Buy on Opus Genetics (IRD)

TIPRANKS
·
Sep 13

Opus Genetics Posts OPGx-BEST1 Phase 1/2 Low-Dose Cohort Presentation

Reuters
·
Sep 11

Health Rounds: Experimental Eye Drops Ease Night Vision Problems for Drivers

Reuters
·
Sep 11

Thomas Shrader Reiterates Buy on IRD, Maintains $12 Price Target Amid Encouraging Clinical and Regulatory Progress

TIPRANKS
·
Sep 10

Opus Genetics up over 32%, on Track for Largest Percent Increase Since February 2020

Dow Jones
·
Sep 10

Opus Genetics Reach 52-Week High on Clinical Trial, FDA Progress

Dow Jones
·
Sep 10

Top Midday Gainers

MT Newswires Live
·
Sep 10

U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs

Reuters
·
Sep 10

Opus Genetics price target raised to $16 from $13 at Chardan

TIPRANKS
·
Sep 10

Wedbush Raises Opus Genetics Price Target to $13 From $10, Maintains Outperform Rating

MT Newswires Live
·
Sep 10

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pyxis Oncology (PYXS) and Opus Genetics (IRD)

TIPRANKS
·
Sep 09

Opus Genetics Price Target Maintained with a $13.00/Share by Chardan Capital

Dow Jones
·
Sep 09

Opus Genetics Reports Positive Phase 1/2 Low-Dose Cohort 1 Data for OPGx-BEST1 Gene Therapy in BEST1 Retinal Disease

Reuters
·
Sep 09

Opus Genetics - FDA Aligns on ≥3 Decibels Microperimetry Improvement as Potential Pivotal Endpoint

THOMSON REUTERS
·
Sep 09

Opus Genetics - Opgx-Best1 Demonstrates Favorable Safety with no Serious Adverse Events or Dose-Limiting Toxicities

THOMSON REUTERS
·
Sep 09

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of Opgx-Best1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

THOMSON REUTERS
·
Sep 09

Opus Genetics - Cohort 2 Dosing to Complete in Q4 2026, Topline Data Expected Q2 2027

THOMSON REUTERS
·
Sep 09

Opus Genetics - All Five Participants Show Clinically Meaningful Improvement in Visual Function

THOMSON REUTERS
·
Sep 09

Opus Genetics to Report Phase 1/2 Cohort 1 Topline Data for OPGx-BEST1 Gene Therapy Sept. 9 Webcast

Reuters
·
Sep 02

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

THOMSON REUTERS
·
Aug 20